Rita Dobmeyer is the CEO of the European CRO Galenus G&H AG. Prior to this she was Director of European Consulting and Client Relations for Parexel GmbH, and Director of Phase IV Clinical Services and Post-Marketing Surveillance at IMS Health. Rita is the founder of eight companies and has networks with investors and key opinion leaders around the world. She is a graduate of the University of Kaiserslautern, with a PhD in infection from the German Cancer Research Centre, Heidelberg.

Cofounder of multi-national CRO Inclin, has hands- on experience in pre-clinical pharmacology drug development and extensive experience in clinical project management. He brings over thirty years of experience to an organization recognized for its commitment to quality, clinical experience and high employee retention. He began his career as a research scientist at Cardima, Inc., COR Therapeutics, and Syntex Research.

Bob Clay is a pharmacist with more than 30 years of experience in drug development, leading the global regulatory approval of many products across a range of therapy areas, including more than 15 new active substances. Previously, he was VP of Global Regulatory Affairs at AstraZeneca with responsibility for oncology, infection and personalised healthcare. Bob is a Fellow and Board Member at TOPRA (President in 2017) and a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture. Bob has held significant leadership roles in regulatory affairs in regional and global functions at Pfizer, AstraZeneca and Kinapse.

Liam is the founder of Tecrea, a pioneering R&D company in the field of molecular science. By creating a patented nanotechnology platform, Tecrea provides a unique range of cell and tissue delivery tools that are fully translatable from the lab to the clinic.

Seasoned clinical development executive and research physician, expertise in infectious disease, oncology, and rare diseases. Successfully led global Phase 1 to NDA programs, and built lasting industry relationships for Celegene, BMS, Boehringer Ingelheim, Roche, Novartis, JnJ, and multiple start-up companies. He has held management roles at the Institute for Medical Statics, Frankfurt, and at IMS Health (now IQVIA), covering drug safety services, portfolio optimization, forecasting, and launch and brand management.

J runs the Investment Portfolio for Pilot Group, a principle shareholder in Sanoderm. He is the operational partner on a number of early-stage companies and a Consultant Active Partners